NASDAQ:BLFS

BioLife Solutions Stock Forecast, Price & News

$45.64
+0.38 (+0.84 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$44.03
$45.95
50-Day Range
$31.07
$48.55
52-Week Range
$18.20
$49.47
Volume103,837 shs
Average Volume289,806 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.46
30 days | 90 days | 365 days | Advanced Chart
Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.


BioLife Solutions logo

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

519th out of 2,218 stocks

Electromedical Equipment Industry

11th out of 65 stocks

Analyst Opinion: 2.4Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

Is BioLife Solutions a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions
or view top-rated stocks.

What stocks does MarketBeat like better than BioLife Solutions?

Wall Street analysts have given BioLife Solutions a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioLife Solutions wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,420,000 shares, an increase of 30.3% from the June 15th total of 1,090,000 shares. Based on an average daily trading volume, of 276,900 shares, the short-interest ratio is currently 5.1 days. Currently, 3.9% of the shares of the company are short sold.
View BioLife Solutions' Short Interest
.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioLife Solutions
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings data on Wednesday, May, 12th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.02. The medical equipment provider had revenue of $16.85 million for the quarter, compared to analysts' expectations of $15.60 million. BioLife Solutions had a negative net margin of 39.34% and a negative trailing twelve-month return on equity of 0.35%.
View BioLife Solutions' earnings history
.

How has BioLife Solutions' stock been impacted by Coronavirus?

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLFS stock has increased by 272.6% and is now trading at $45.64.
View which stocks have been most impacted by COVID-19
.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $106 million-115 million, compared to the consensus revenue estimate of $105.65 million.

What price target have analysts set for BLFS?

9 Wall Street analysts have issued 1-year price targets for BioLife Solutions' stock. Their forecasts range from $33.00 to $61.00. On average, they expect BioLife Solutions' stock price to reach $50.38 in the next year. This suggests a possible upside of 10.4% from the stock's current price.
View analysts' price targets for BioLife Solutions
or view top-rated stocks among Wall Street analysts.

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:

What is Mike Rice's approval rating as BioLife Solutions' CEO?

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioLife Solutions' key competitors?

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $45.64.

How much money does BioLife Solutions make?

BioLife Solutions has a market capitalization of $1.84 billion and generates $48.09 million in revenue each year. The medical equipment provider earns $2.67 million in net income (profit) each year or $0.01 on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 193 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

Where are BioLife Solutions' headquarters?

BioLife Solutions is headquartered at 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.